Clinical Trial Update: Tocilizumab for Chronic Graft-versus-Host Disease Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of tocilizumab for chronic graft-versus-host disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Graft Versus Host Disease | Phase 2 | Status: WITHDRAWN